The two therapies often let enough cancer cells survive to defeat the treatment.
The combination of the two therapies, the authors found, produced the most rapid recovery and protected against sudden suicidal urges.
"If the goal is to prevent or delay progression, the combination of the two therapies is better than either alone," he said.
Two therapies are proposed for this trial.
Determining which of these two therapies is most cost-effective was the goal of this study.
The combination of these two therapies may produce synergistic anti-tumor effects.
A formal comparison of these two therapies in terms of cardiovascular morbidity and mortality is lacking.
When PRRT with chemotherapeutics are being combined, also potential negative interactions between the two therapies should be taken into consideration.
In addition, neither the technical feasibility nor the complication rate associated with these two therapies in tandem has been evaluated.
Randomised direct comparative trials are therefore the only objective way to evaluate the relative efficacy of two therapies.
If two therapies were equally effective, 65% would choose an ALT and 11% would prefer the conventional therapy (24% having no preference).
